

Supplementary Table 9: Baseline characteristics of patients

Indication	Advanced index drug	Sex	Age at index (years)	
			Mean	Median
CD	Adalimumab	female	38,6	38,0
CD	Adalimumab	male	39,4	39,0
CD	Infliximab	female	39,0	38,0
CD	Infliximab	male	37,6	36,0
CD	Ustekinumab	female	46,5	44,5
CD	Ustekinumab	male	41,5	41,0
CD	Vedolizumab	female	43,9	42,0
CD	Vedolizumab	male	48,6	51,0
UC	Adalimumab	female	41,7	41,0
UC	Adalimumab	male	44,6	46,0
UC	Golimumab	female	38,2	38,0
UC	Golimumab	male	44,9	45,0
UC	Infliximab	female	40,3	37,0
UC	Infliximab	male	41,8	41,0
UC	Tofacitinib	female	47,6	48,0
UC	Tofacitinib	male	45,5	46,0
UC	Ustekinumab	female	48,5	53,0
UC	Ustekinumab	male	42,2	41,0
UC	Vedolizumab	female	43,2	40,0
UC	Vedolizumab	male	46,6	45,0

CD = Crohn's disease (CD) UC = Ulcerative Colitis